Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Intranasal Stimulation Of Long-lasting Immunity Against Aerosol Ricin Challenge With Ricin Toxoid Vaccine Encapsulated In Polymeric Microspheres.

C. Yan, W. Rill, R. Malli, J. Hewetson, H. Naseem, R. Tammariello, M. Kende
Published 1996 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Intranasal (i.n.) immunization with ricin toxoid (RT) vaccine encapsulated in poly (lactide-co-glycolide) microspheres (RT-PLG-Ms) and poly (L-lactide) microspheres (RT-PLA-Ms) stimulated systemic and mucosal immune responses and protected mice from aerosolized ricin intoxication. High titers of anti-ricin IgG2a were stimulated in the serum of mice with one or two doses of RT-Ms 6 weeks postimmunization. However, in the lungs, no IgG2a or total IgG was elicited either with RT-Ms or with aqueous RT. At 6 weeks postimmunization, a single dose of the RT-Ms stimulated secretory IgA (sIgA) in the lungs of four of six mice, but a second immunizing dose did not enhance the stimulation. A single dose of aqueous RT vaccine failed to stimulate sIgA in the lungs, while, a second dose induced sIgA in 50% of the mice. One or two i.n. doses of RT-Ms protected most of the mice against lethal aerosol-delivered ricin toxin 6 weeks postimmunization. In contrast, protection was absent or marginal after one or two doses of aqueous RT vaccine. In both studies, the protection against lethal aerosol challenge was significantly better with one dose of RT-Ms than with two doses of aqueous vaccine, which may be attributed to the induction of sIgA in the lungs and the serum. Duration of the IgG2a and IgA in the serum, particularly that of IgG2a was much longer after the administration of RT-Ms than after the aqueous vaccine. The geometric mean IgG2a titers stimulated with two doses of RT-Ms remained high during 40 weeks postimmunization and were up to 25 times higher than the titers induced with aqueous RT vaccine. After 6 weeks, the IgG2a induced by two doses of aqueous vaccine was no longer detectable. Persistence of antibody response was predictive of efficacy. At 1 year postimmunization with two doses of RT-Ms, 100% of mice were protected against lethal ricin challenge. However, at the same time no protection was afforded by two doses of aqueous RT. The results of the present study consistently demonstrated the advantages of microencapsulated RT vaccine to stimulate effective and long-lasting protection by i.n. administration.
This paper references
10.1016/0264-410X(92)90395-Z
Intranasal immunization with bacterial polysaccharide containing liposomes enhances antigen-specific pulmonary secretory antibody response.
E. Abraham (1992)
10.1016/0161-5890(91)90074-T
Immunological adjuvants: desirable properties and side-effects.
A. Allison (1991)
10.1016/0264-410X(94)00026-J
Dependence of ricin toxoid vaccine efficacy on the structure of poly(lactide-co-glycolide) microparticle carriers.
C. Yan (1995)
10.1016/0264-410X(94)90251-8
Activation of systemic and mucosal immune response following nasal administration of liposomes.
Y. Aramaki (1994)
10.1016/0264-410X(89)90055-8
Intranasal immunization with proteoliposomes protects against influenza.
N. el Guink (1989)
10.1016/0300-9629(93)90342-2
Peptide and protein drug delivery
V. Lee (1991)
Biodegradable microparticles as controlled release antigen delivery systems.
D. O'hagan (1991)
10.1016/0264-410X(95)93129-W
Mucosal immunoadjuvant activity of liposomes: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with an influenza subunit vaccine and coadministered liposomes.
A. de Haan (1995)
10.1152/AJPLEGACY.1947.150.1.70
Measurement of the respiratory volumes of laboratory animals.
Arthur C. Guyton (1947)
10.1016/0168-3659(90)90133-E
Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the peyer's patches
J. Eldridge (1990)
10.1016/0264-410X(94)00008-B
Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles.
E. Cahill (1995)
Heat-labile IgG2a antibodies affect cure of Trypanosoma musculi infection in C57BL/6 mice.
D. S. Wechsler (1986)
10.1016/0264-410X(89)90156-4
Microparticles as potentially orally active immunological adjuvants.
D. O'hagan (1989)
In vivo antitumor effects of monoclonal antibodies with different immunoglobulin classes.
M. Seto (1983)
10.1016/0264-410X(94)90112-0
New strategies for using mucosal vaccination to achieve more effective immunization.
R. Walker (1994)
10.1016/0168-3659(94)90233-X
Characterization and morphological analysis of protein-loaded poly(lactide-co-glycolide) microparticles prepared by water-in-oil-in-water emulsion technique
C. Yan (1994)
10.1177/030098589603300306
Lesions of Acute Inhaled Lethal Ricin Intoxication in Rhesus Monkeys 1 2
C. Wilhelmsen (1996)
10.1073/PNAS.79.15.4761
IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells.
D. Herlyn (1982)
10.1016/0264-410X(94)90092-2
Biodegradable microspheres as controlled-release tetanus toxoid delivery systems.
M. J. Alonso (1994)
10.1016/0264-410X(94)90003-5
Potential of polymer microencapsulation technology for vaccine innovation.
W. Morris (1994)
10.1016/0264-410X(91)90056-C
Improvement of hepatitis B vaccine by the use of a new adjuvant.
N. Byars (1991)



This paper is referenced by
Chapter 21 Medical Countermeasures Introduction Bacterial and Rickettsial Diseases Anthrax Tularemia Plague Glanders and Melioidosis Brucellosis Q Fever Virology Alphaviruses Smallpox Viral Hemorrhagic Fevers
J. Rusnak (2009)
10.1016/J.VACCINE.2006.01.031
Inducing systemic and mucosal immune responses to B-T construct of F1 antigen of Yersinia pestis in microsphere delivery.
Vinita Tripathi (2006)
10.2165/00126839-200607050-00001
Current Efforts on Generation of Optimal Immune Responses against HIV through Mucosal Immunisations
M. Vajdy (2006)
10.1016/J.ADDR.2005.01.016
Production of vaccines against leading biowarfare toxins can utilize DNA scientific technology.
J. Middlebrook (2005)
10.1016/S0168-3659(00)00199-1
Recent advances in mucosal vaccine development.
H. Chen (2000)
10.1128/CVI.00275-17
Protein Structure Facilitates High-Resolution Immunological Mapping
Madison Zuverink (2017)
10.1080/21645515.2015.1038446
Strong protection against ricin challenge induced by a novel modified ricin A-chain protein in mouse model
Tao Zhang (2015)
10.1016/S0264-410X(97)80912-7
Controlled release microparticles as a single dose diphtheria toxoid vaccine: immunogenicity in small animal models.
M. Singh (1998)
10.1201/9781420046625-23
Ricin and related toxins: review and perspective.
C. B. Millard (2008)
10.1016/j.addr.2015.03.007
Delivery strategies to enhance oral vaccination against enteric infections.
Christopher J. H. Davitt (2015)
10.1007/978-1-4939-3387-7_38
Ricin-Holotoxin-Based Vaccines: Induction of Potent Ricin-Neutralizing Antibodies.
T. Sabo (2016)
10.1201/B10837-17
Animal Models in Biodefense Research
M. Suckow (2011)
Inductive pathways leading to rat tear IgA antibody responses.
D. M. Ridley Lathers (1998)
10.4333/KPS.2004.34.1.001
Improved Antigen Delivery Systems with PLGA Microsphere for a Single-Step Immunization
Mi-Kyeong Yoon (2004)
Towards the development of a multicomponent, nanoscale oral vaccine delivery system targeting infectious bursal disease (IBD)
Wendy Marie Pettit (2013)
10.1016/S0165-0378(99)00005-4
The potential use of sperm antigens as targets for immunocontraception; past, present and future.
J. Frayne (1999)
10.1163/156856299X00892
Intranasal immunization against influenza virus using polymeric particles.
D. Lemoine (1999)
10.1002/9780470744307.GAT152
Ricin: Chemistry, Sources, Exposures, Toxicology and Medical Aspects
J. Lord (2009)
10.1016/S0264-410X(97)00249-1
Intra nasal administration of poly-lactic acid microsphere co-encapsulated Yersinia pestis subunits confers protection from pneumonic plague in the mouse.
J. Eyles (1998)
10.1111/j.1440-1711.2004.01288.x
Mucosal adjuvants and delivery systems for protein‐, DNA‐ and RNA‐based vaccines
M. Vajdy (2004)
10.1080/08958370701432124
Inhalation Toxicology of Ricin Preparations: Animal Models, Prophylactic and Therapeutic Approaches to Protection
G. Griffiths (2007)
10.2174/157341311794653541
Nanocarriers for Transmucosal Vaccine Delivery
S. Jain (2011)
Biodegradable Microparticles as Non-Live Viral Vectors for Respiratory Tract Vaccination.
B. Earley (2001)
10.1128/IAI.02088-05
Immunoglobulin A Antibodies against Ricin A and B Subunits Protect Epithelial Cells from Ricin Intoxication
N. Mantis (2006)
Ricina: una fitotoxina de uso potencial como arma
R. Pita (2004)
10.1007/978-1-4419-1266-4_8
Ricin: A Possible, Noninfectious Biological Weapon
M. Maman (2009)
10.1007/978-3-642-27470-1
Ricin and Shiga Toxins
N. Mantis (2012)
10.1016/S0264-410X(00)00264-4
Microencapsulated enterotoxigenic Escherichia coli and detached fimbriae for peroral vaccination of pigs.
C. B. Felder (2000)
10.1007/82_2011_193
Immunity to ricin: fundamental insights into toxin-antibody interactions.
Joanne M. O’Hara (2012)
10.1016/J.ADDR.2005.01.014
Microencapsulated subunit vaccine approach to enterotoxigenic Escherichia coli and other mucosal pathogens.
W. Byrd (2005)
10.1016/J.ADDR.2005.01.010
Particulate delivery systems for biodefense subunit vaccines.
Vincent W. Bramwell (2005)
10.1016/S0169-409X(98)00045-3
Microparticles and polymers for the mucosal delivery of vaccines.
O’Hagan (1998)
See more
Semantic Scholar Logo Some data provided by SemanticScholar